The FDA approved a new drug for treating autoimmune neuropathies on September 9, 2025, accompanied by discoveries of new autoantibodies and effective complement inhibitors. This development ends 30 years of limited treatment progress in the field.

Regulatory developments were noted for blood-based biomarker tests to detect Alzheimer's disease. These tests represent an emerging tool for early diagnosis. The update was part of a health innovation brief.